GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
2.1k
c/trialwatch·posted 3 months ago by u/yara_mensah

[Question] endpoint — what am I missing here

Discussion Long Haul ×7 Receipts ×3

endpoint — what am I missing here. I would rather ask a basic question now than get this wrong quietly for two months.

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

Read a press release and the publication three months apart. The hedging in the second one was substantial.

Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.

3,126 up / 1,066 down75% upvoted67 commentsid 11g02118 Apr 2026

67 comments

30 in this archive, depth 5

best — the order this archive was captured in

u/hazard_ratio_halMOD353 points·3 months ago

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

replysharereportpermalink
u/nightowl_injector151 points·3 months ago

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

replysharereportpermalink
u/ewan_tulloch104 points·3 months ago

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink
u/anders_karlsen34 points·3 months ago

intention to treat versus completers changes the number substantially

replysharereportpermalink
u/enzo_ferrari208 points·3 months ago

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

replysharereportpermalink
u/yara_bakken69 points·3 months ago

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

replysharereportpermalink
u/yara_mensahOP-2 points·3 months ago

The registered protocol is public.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

replysharereportpermalink
u/yara_mensahOP1 point·3 months ago

Is that intention-to-treat or completers?

replysharereportpermalink
u/paper_trail_paulavetting1 point·3 months ago

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

replysharereportpermalink
u/yara_mensahOP1 point·3 months ago

Which trial, and which arm?

replysharereportpermalink
u/ferran_dahlberg1 point·3 months ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/anders_vermeulen124 points·3 months ago

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

replysharereportpermalink
u/ewan_tulloch28 points·3 months ago

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

replysharereportpermalink
u/anders_vermeulen23 points·3 months ago

Push back: an open-label extension tells you about the people who stayed. That is a different question.

replysharereportpermalink
u/ahmed_iyer14 points·3 months ago·edited

Push back: an open-label extension tells you about the people who stayed.

anders_vermeulen is right about the programme names. They are different populations with different endpoints.

replysharereportpermalink
[deleted]9 points·3 months ago

[deleted]

replysharereportpermalink
u/arne_ilunga54 points·3 months ago

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

replysharereportpermalink
u/alcohol_aversion30 points·3 months ago·edited

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/hub_opssite staff24 points·3 months ago

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

replysharereportpermalink
u/forest_plot_fionastats114 points·3 months ago·edited

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

replysharereportpermalink
u/careful_gradient_again49 points·3 months ago

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

replysharereportpermalink
u/nayeli_fonseca58 points·3 months ago

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

replysharereportpermalink
u/sten_palacios27 points·3 months ago·edited

Intention-to-treat analyses everybody randomised regardless of what they did afterwards.

Agreed. And the interval, not the point estimate, is what the trial actually established.

replysharereportpermalink
u/milan_villalobos8 points·3 months ago

the confidence interval is the finding, the point estimate is the headline

replysharereportpermalink
u/anders_karlsen13 points·3 months ago

a mean is not a promise

replysharereportpermalink
u/nightowl_injector17 points·3 months ago

a press release is not a publication

replysharereportpermalink
u/rt_shift_reggie25 points·3 months ago

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

replysharereportpermalink
u/week_one_wanda11 points·3 months ago

phase 2 finds a dose, phase 3 measures the effect

replysharereportpermalink
u/rt_shift_reggie59 points·3 months ago·edited

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/arne_ilunga45 points·3 months ago

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.